CClinicalTrials.gg
WithdrawnNCT03408015Updated May 17, 2019

Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

A Phase 4 interventional study of Lifitegrast in Ocular Discomfort, Ocular Inflammation and Dry Eye, sponsored by University of Alabama at Birmingham. Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-17.

Sponsored by University of Alabama at Birmingham · Phase 4, Interventional, and Basic science

Why this study was withdrawn
Study timing was poor.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action.

02

Conditions studied

  • Ocular Discomfort
  • Ocular Inflammation
  • Dry Eye
  • Contact Lens Complication
  • Keratoconjunctivitis Sicca

Keywords

  • dry eye disease
  • neutrophil
  • T cell
  • lifitegrast
  • contact lens discomfort
  • ocular surface homeostasis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Able to understand and sign an informed consent and HIPAA privacy document
  • Greater than 18 years of age at time of informed consent
  • Able and willing to follow protocol instructions
  • Capable of performing at-home eye wash
  • Must be willing to drop off samples and comply with study visit procedures
  • For contact lens wearers, must wear lenses at least four hours per day, four days per week

Exclusion criteria

Exclusion Criteria:

  • Current cigarette smokers
  • Current participation in any investigational drug or device study. If subjects choose to participate in another investigational drug or device study, they will be discontinued from this study protocol.
  • Current pregnancy or nursing as indicated by self-report. While not a safety issue, pregnancy or nursing influences the biochemical composition of the tear film.
  • Any systemic health conditions that alter tear film physiology
  • A history of ocular surgery within the past 12 months
  • Any active ocular infection or inflammation
  • Any present use of Accutane or ocular medications
  • Any history of significant adverse reaction to lifitegrast or other components of the drug product, or contraindication to the use of lifitegrast or other components of the drug product
  • Any prior exposure to lifitegrast.
  • For normal and dry eye subjects, any history of contact lens wear within the past three months.
  • For contact lens wearers, any change of soft contact lens brand or care solutions within 30 days prior to screening or any anticipation of changing current type/brand of contact lenses or care solutions throughout the 84 day study
  • Any condition, which in the examiner's opinion, may put the subject at significant risk, confound study results, or interfere with their participation in the study.
04

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Normal, asymptomatic non-lens wearers

    Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.

    Drug: Lifitegrast

  • Experimental
    Dry eye subjects, non-lens wearers

    Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.

    Drug: Lifitegrast

  • Experimental
    Contact lens wearers with discomfort

    Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.

    Drug: Lifitegrast

Interventions

  • DrugLifitegrast

    Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.

    Also known as: Xiidra

05

What researchers measure

Primary outcomes

  1. Change from baseline in the total number of T cells recovered from the closed eye to day 84

    Subjects will be trained and required to collect their closed eye tears at home, using a gentle saline rinse of the ocular surface. Enumeration of recovered T cells will be performed by flow cytometry.

    Time frame: Baseline to day 84

Secondary outcomes

  1. Change from baseline in the total number of neutrophils recovered from the closed eye to day 84.

    Subjects will be trained and required to collect their closed eye tears at home, using a gentle saline rinse of the ocular surface. Enumeration of recovered neutrophils will be performed by flow cytometry.

    Time frame: Baseline to day 84.

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03408015
Lead sponsor
University of Alabama at Birmingham
Collaborators
Shire
Responsible party
Kelly Nichols (Dean, Principal Investigator, UAB School of Optometry, University of Alabama at Birmingham) — Principal investigator
First posted
Jan 23, 2018
Start date
Jan 2019 (estimated)
Primary completion
Jan 30, 2019
Completion
Jan 30, 2019
Last update
May 17, 2019

Study contacts

Kelly K Nichols, OD MPH PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion